EASTAMPTON, NJ, Sept. 28, 2016 /PRNewswire/ - Epicore BioNetworks Inc. is pleased to announce that a new director has joined the board, effective September 6, 2016. The Board welcomes Mr. Donald R. Siemens of Langley, B.C., Canada. Mr. Siemens holds a bachelor's degree from the University of British Colombia and has over 40 years' experience as a chartered accountant. He has held partnership positions with major accounting firms, senior executive positions in industry and experience as a self-employed financial services executive. The Board expects that his knowledge and experience will be of great benefit to Epicore's plan to develop commercial alliances.
The Board of Directors has approved issuance to Mr. Siemens of 50,000 options to buy Epicore common shares. The grants follow Company board compensation policy. The options being issued have an exercise price of C$0.70 per share and expire in five years. The 50,000 options granted is equivalent to 0.2% of Epicore's issued common stock. The Epicore Stock Option Plan was approved by shareholders at the Company's Annual General and Special Meetings of Shareholders.
Epicore BioNetworks Inc. is a leading producer of environmental biotechnology and animal nutrition products. It manufactures in the USA and markets worldwide to a variety of industries to reduce environmental pollution and increase operational productivity.
Epicore BioNetworks Inc. is a public corporation with a registered office in Calgary, Alberta, Canada and with shares listed on the TSX Venture Exchange (symbol EBN). [The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.]
For more information:
Last updated on: 30/09/2016
PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.